Skip to main content

Clinical Trials

The Canadian Cancer Trials Group (CCTG) supports national and international multicentre phase I-III cancer clinical research trials aimed at improving the survival and quality of life of cancer patients across all cancer types. The scientific agenda for the group is developed by clinical researchers across Canada and beyond, includes trials of new cancer agents, novel radiation and surgical techniques, as well as interventions to improve patient quality of life.

If you are a CCTG member and need to access the full trials pages please click here.

The links below will take you to pages that list all the current CCTG trials with a brief description. If you are interested in volunteering for a trial we suggest that you discuss the opportunity with your care team.

If you are a patient or caregiver and are looking for other information about clinical trials a complete listing of clinical trials being conducted in Canada, including the locations where they are being conducted, can be found here: Canadian Cancer Trials.  And if you are interested in learning about participating in a clinical trial more information can be found here: www.itstartswithme.ca

 

How can I participate in a clinical trial

 

How can I participate in a clinical trial

CCTG PR24 ASCENDE-SBRT trial to determine whether stereotactic body radiotherapy (SBRT) can replace the current standard radiation treatment (brachytherapy boost)

CCTG PR24 trial opens to investigate Stereotactic Ablative Body Radiotherapy effectiveness in treating prostate cancer

Now open the CCTG PR24 ASCENDE-SBRT trial to determine whether stereotactic body radiotherapy (SBRT) can replace the current standard radiation treatment (brachytherapy boost) for men with unfavourable risk prostate cancer. SBRT is a non-invasive, high precision, less costly radiation technique that results in similar outcomes and tolerability to brachytherapy boost.

More >>
 
CCTG HD12 a hematology trial investigating targeted therapy for early-stage Hodgkin lymphoma opens in Canada

CCTG HD12 a hematology trial investigating targeted therapy for early-stage Hodgkin lymphoma opens in Canada

Researchers will compare the usual treatment for Hodgkin lymphoma, with a new treatment that takes the standard combination drug treatment replacing one of the drugs with brentuximab vedotin that may be more effective and cause fewer side effects for patients.

More >>
 
CIHR funding announced for CCTG PR25

CIHR funding announced for CCTG PR25

The CIHR has announced funding, $1,828,350 over 6 years, for the CCTG PR25 trial, a metastatic prostate cancer personalized medicine study investigating the addition platinum-based chemotherapy to standard of care chemotherapy to evaluate markers believed to predict benefit.

More >>
 
CIHR has announced $3,056,176 in funding over 5 years, for the TACtful trial

CIHR has announces funding for the TACtful cell therapy trial

CIHR has announced $3,056,176 in funding over 5 years, for the TACtful trial investigating a novel cell therapy using the immune system to treat people with relapsed and refractory multiple myeloma.

More >>